# Gilead Sciences, Inc. (GILD) — Q4-2013 Earnings Results

**Report date:** 2014-02-04 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q4-2013

## Post-Earnings Brief

### Headline

Gilead Sciences Beats on EPS, Stock Down N/A%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.55 | N/A | +12.24% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism about future growth. They emphasized the potential of their product pipeline and upcoming trials.

**Key quotes:**

> Management expressed confidence in the company's ongoing product pipeline.

> They highlighted the importance of upcoming clinical trials.

> There was a focus on maintaining strong market presence.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

This earnings report indicates that Gilead Sciences is performing well in terms of earnings per share, exceeding expectations. However, the lack of revenue data and guidance leaves some uncertainty regarding future performance. Investors will be watching closely for updates on product developments and clinical trials, which could impact the stock moving forward.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q4-2013_